Amgen
Biotech company creating biologic medicines
Business Performance and Analytics Manager - Global Supply Chain
About the job
- 8-13 years of experience in Supply Chain, Business Analytics, Data Analytics, Operations, Finance, Engineering, or related business functions, or an equivalent combination of education and relevant experience consistent with qualification requirements.
- Serve as the primary integrator of business performance across the Global Planning Network and Site Supply Chain organizations, ensuring a unified view of end-to-end supply chain performance.
- Foster partnerships across Supply Planning, Raw Materials Planning, Digital Technology, and Site Supply Chain teams to align performance measures, priorities, and business objectives.
- Establish common KPI definitions, reporting standards, and governance processes across global planning and site operations.
- Connect operational, planning, and financial insights into a cohesive business performance narrative for executive decision-making.
- Facilitate cross-functional performance reviews, resolve performance gaps, and drive aligned improvement initiatives across the global network.
- Lead the Business Performance & Analytics team supporting the Global Planning Network and Site Supply Chain organizations.
- Define the analytics strategy, operating model, priorities, and roadmap aligned with Global Planning objectives.
- Establish governance for Global Supply Chain Planning KPI reporting, performance management, and business analytics.
- Ensure timely delivery of recurring and ad hoc reporting.
- Translate business strategy into performance metrics and executive dashboards with Global Planning.
- Present business insights and recommendations to Planning and Site Supply Chain leadership.
- Provide strategic analytics leadership across Supply Planning, Raw Materials Planning, Inventory Planning, and Integrated Business Planning processes.
- Partner with planning leaders to identify trends, risks, constraints, and opportunities that improve planning performance and supply reliability.
- Lead analytics supporting manufacturing and site supply chain operations.
- Drive standardization of metrics and reporting processes across manufacturing sites.
- Lead the design and continuous improvement of enterprise analytics capabilities, including executive dashboards, KPI scorecards, self-service reporting, data visualization, predictive analytics, and artificial-intelligence-enabled decision support.
- Collaborate with the Global Supply Chain Digital team to develop and support reporting platforms including Tableau, Power BI, SAP Analytics Cloud, and other enterprise analytics tools.
- Partner with Digital Technology and SAP teams to prioritize enhancements, improve reporting architecture, and increase automation across supply chain processes.
- Partner with Finance to improve visibility of supply chain financial performance, including budget tracking, cost center performance, logistics costs, inventory carrying costs, scrap performance, forecast accuracy, and operational cost drivers.
- Develop analytics that enable proactive financial decision-making and quantify business value delivered through supply chain improvements.
- Lead initiatives to simplify processes, automate reporting, improve data quality, and standardize analytics.
- Drive continuous improvement projects that improve operational efficiency, reporting effectiveness, and business outcomes.
- Lead and develop the Business Performance & Analytics Analyst team.
- Prioritize and allocate work across the team to meet business commitments.
- Ensure consistent KPI definitions, reporting standards, and data quality across supported functions.
- Facilitate cross-functional performance reviews and support governance forums.
- Drive continuous improvement, automation, and analytics capability within the team.
- Coach and develop team members while fostering a collaborative, customer-focused culture.
- Experience leading or supervising business analytics, business intelligence, supply chain, planning, or operations teams in a complex global organization.
- Strong knowledge of end-to-end supply chain planning processes, including Supply Planning, Raw Materials Planning, Inventory Planning, Integrated Business Planning, Manufacturing, Procurement, Logistics, and Site Supply Chain operations.
- Experience developing enterprise performance dashboards, KPI frameworks, executive reporting, and business performance scorecards.
- Knowledge of SAP S/4HANA, SAP ECC, SAP Fiori, SAP IBP, Tableau, Power BI, SAP Analytics Cloud, BusinessObjects, SQL, Python, or Databricks.
- Experience leading process improvement, reporting standardization, automation, and digital transformation initiatives.
- Strong understanding of data governance, data quality, and master data management principles.
- Experience partnering with Finance on business performance reporting, budgeting, forecasting, and operational performance analysis.
- Analytical, communication, presentation, and stakeholder management skills, including the ability to translate complex data into meaningful business insights for diverse audiences.
- Ability to lead teams, develop talent, manage competing priorities, and deliver high-quality results in a fast-paced, matrixed environment.
About the company
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
- Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
- MariTide now has nine ongoing and three planned Phase 3 studies across obesity.
What critics are saying
- Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
- FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
- If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.
What makes Amgen unique
- Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
- IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
- Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.
Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.
Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.
Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.
Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.